
Togo African Region





## I. Epidemiological profile

Population (UN Population Division)	2017	%
High transmission (>1 case per 1000 population)	7.8M 1	100
Low transmission (0-1 case per 1000 population)	0	-
Malaria free (0 cases)	0	-
Total	7.8M	

Parasites and vectors				
Major plasmodium species:	P.falciparı	um: 100 (%) , P.vi	vax: 0 (%)	
Major anopheles species:	An. gamb	iae, An. funestus	, An. melas, An. arabie	ensis
Reported confirmed cases (health	facility):	1 209 034	Estimated cases:	2.9M [2M, 4.3M]
Confirmed cases at community le	vel:	546 543		
Confirmed cases from private sec	tor:	-		
Reported deaths:		995	Estimated deaths:	5.3K [4.4K, 6.3K]

## II. Intervention policies and strategies

Intervention	Policies/Strategies	Yes/	Year
Intervention	Policies/Strategies	No	adopted
ITN	ITNs/LLINs distributed free of charge	Yes	2004
	ITNs/LLINs distributed to all age groups	Yes	2011
IRS	IRS is recommended	Yes	2011
	DDT is used for IRS	No	-
Larval control	Use of Larval Control	No	
IPT	IPT used to prevent malaria during pregnancy	Yes	2003
Diagnosis	Patients of all ages should receive diagnostic test	Yes	2010
	Malaria diagnosis is free of charge in the public sector	No	2012
Treatment	ACT is free for all ages in public sector	No	2013
	The sale of oral artemisinin-based monotherapies (oAMTs)	is banned	2011
	Single dose of primaquine (0.25 mg base/kg) is used as gametocidal medicine for P. falciparum	No	-
	Primaquine is used for radical treatment of P. vivax	No	-
	G6PD test is a requirement before treatment with primaquine	-	-
	Directly observed treatment with primaquine is undertaken	No	-
	System for monitoring of adverse reaction to antimalarials exists	Yes	2009
Surveillance	ACD for case investigation (reactive)	No	-
	ACD at community level of febrile cases (pro-active)	No	2013
	Mass screening is undertaken	No	-
	Uncomplicated P. falciparum cases routinely admitted	Yes	2007
	Uncomplicated P. vivax cases routinely admitted	No	-
	Case and foci investigation undertaken	No	
	Case reporting from private sector is mandatory	No	-

Antimalaria treatment policy  First-line treatment of unconfirmed malaria  First-line treatment of P. falciparum  For treatment failure of P. falciparum  Treatment of severe malaria  AS; AF  Treatment of P. vivax  Dosage of primaquine for radical treatment of P. vivax  Type of RDT used  Therapeutic efficacy tests (clinical and parasitological failure, %)  Medicine  Year  Min Median  Max Follow-up  No. of studie  AL  2012-2013  0  2.7  3  28 days  3  Resistance status by insecticide class (2010-2017) and use of class for malaria  Insecticide class  Years  (%) sites¹  Vectors²	S+AQ - S+AQ - 
First-line treatment of P. falciparum  For treatment failure of P. falciparum  Treatment of severe malaria  Treatment of P. vivax  Dosage of primaquine for radical treatment of P. vivax  Type of RDT used  Therapeutic efficacy tests (clinical and parasitological failure, %)  Medicine Year Min Median Max Follow-up No. of studies AL 2012-2013 0 2.7 3 28 days 3 AS+AQ 2012-2013 0 0 3.8 28 days 3 ARS+AQ states by insecticide class (2010-2017) and use of class for malarial failure in the failure of the	S+AQ
For treatment failure of P. falciparum  Treatment of severe malaria  AS; A!  Treatment of P. vivax  Dosage of primaquine for radical treatment of P. vivax  Type of RDT used  Therapeutic efficacy tests (clinical and parasitological failure, %)  Medicine Year Min Median Max Follow-up No. of studie AL 2012-2013 0 2.7 3 28 days 3 AS+AQ 2012-2013 0 0 3.8 28 days 3  Resistance status by insecticide class (2010-2017) and use of class for malaria	м; QN -
Treatment of Severe malaria  Treatment of P. vivax  Dosage of primaquine for radical treatment of P. vivax  Type of RDT used  Therapeutic efficacy tests (clinical and parasitological failure, %)  Medicine Year Min Median Max Follow-up No. of studie AL 2012-2013 0 2.7 3 28 days 3 AS+AQ 2012-2013 0 0 3.8 28 days 3 SResistance status by insecticide class (2010-2017) and use of class for malaria	
Treatment of P. vivax  Dosage of primaquine for radical treatment of P. vivax  Type of RDT used  Therapeutic efficacy tests (clinical and parasitological failure, %)  Medicine Year Min Median Max Follow-up No. of studie AL 2012-2013 0 2.7 3 28 days 3 AS+AQ 2012-2013 0 0 3.8 28 days 3  Resistance status by insecticide class (2010-2017) and use of class for malaria	
Dosage of primaquine for radical treatment of P. vivax  Type of RDT used  Therapeutic efficacy tests (clinical and parasitological failure, %)  Medicine Year Min Median Max Follow-up No. of studie AL 2012-2013 0 2.7 3 28 days 3  AS+AQ 2012-2013 0 0 3.8 28 days 3  Resistance status by insecticide class (2010-2017) and use of class for malaria	P.f only
Type of RDT used  Therapeutic efficacy tests (clinical and parasitological failure, %)  Medicine Year Min Median Max Follow-up No. of studie AL 2012-2013 0 2.7 3 28 days 3  AS+AQ 2012-2013 0 0 3.8 28 days 3  Resistance status by insecticide class (2010-2017) and use of class for malaria	P.f only
Therapeutic efficacy tests (clinical and parasitological failure, %)  Medicine Year Min Median Max Follow-up No. of studie AL 2012-2013 0 2.7 3 28 days 3  AS+AQ 2012-2013 0 0 3.8 28 days 3  Resistance status by insecticide class (2010-2017) and use of class for malaria	P.f only
Medicine     Year     Min     Median     Max     Follow-up     No. of studie       AL     2012-2013     0     2.7     3     28 days     3       AS+AQ     2012-2013     0     0     3.8     28 days     3       Resistance status by insecticide class (2010-2017) and use of class for malaria	
AL     2012-2013     0     2.7     3     28 days     3       AS+AQ     2012-2013     0     0     3.8     28 days     3       Resistance status by insecticide class (2010-2017) and use of class for malaria	
AS+AQ 2012-2013 0 0 3.8 28 days 3 Resistance status by insecticide class (2010-2017) and use of class for malaria	es Species
Resistance status by insecticide class (2010-2017) and use of class for malaria	P. falciparum
	P. falciparum
Inserticide class Years (%) sites 1 Vectors 2	vector control (2017)
	Used <sup>3</sup>
Carbamates 2011-2013 100% (5) An. gambiae s	i.l. No
Organochlorines 2011-2013 100% (6) An. gambiae s	i.l. No
Organophosphates 2011-2013 0% (2) -	No
Pyrethroids 2011-2013 100% (7) An. gambiae s	s.l. Yes
<sup>1</sup> Percent of sites for which resistance confirmed and total number of sites that reported data (n	)
<sup>2</sup> Principal vectors that exhibited resistance	
<sup>3</sup> Class used for malaria vector control in 2017	